Patents by Inventor Patrick Finn

Patrick Finn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250114760
    Abstract: This document provides bead dispensing devices that can be configured to mount onto a container (e.g., a test tube containing sterile beads) and allow for a set number of beads (e.g., glass beads) to be dispensed.
    Type: Application
    Filed: October 5, 2023
    Publication date: April 10, 2025
    Inventors: James Patrick Finn, IV, Matthew Samuel Finn
  • Publication number: 20250090684
    Abstract: This disclosure relates to mRNA therapy for the treatment of glycogen storage disease type 1a (GSD1a). mRNAs for use in the invention, when administered in vivo, encode glucose-6-phosphatase (G6PC). mRNA therapies of the disclosure increase and/or restore deficient levels of G6PC expression and/or activity in subjects.
    Type: Application
    Filed: July 26, 2022
    Publication date: March 20, 2025
    Inventors: Husain Attarwala, Jingsong Cao, Patrick Finn, Simone Mori
  • Patent number: 12252504
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: March 18, 2025
    Assignee: Genzyme Corporation
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Patent number: 12251430
    Abstract: The present application provides methods of treating Pompe disease such as infantile-onset Pompe disease (IOPD) using a pharmaceutical composition comprising an oligosaccharide-acid ?-glucosidase (GAA) conjugate, such as avalglucosidase alfa. Also provided are formulations of the oligosaccharide-GAA conjugates.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: March 18, 2025
    Assignee: Genzyme Corporation
    Inventors: Kristina An Haack, Patrick Finn, Catherine Wilson
  • Publication number: 20250026821
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Application
    Filed: July 9, 2024
    Publication date: January 23, 2025
    Applicant: SANOFI
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
  • Publication number: 20240312056
    Abstract: A method for determining a three dimensional, 3D, position of an object; wherein the object is located in a field of view of an optical sensor; wherein the object is located on or above a plane or preferably on a virtual plane. The method comprising the steps of: a) acquiring an image from the optical sensor comprising the object; b) obtaining the 3D position of the optical sensor in a 3D map comprising at least a portion of the field of view of the optical sensor; c) recognizing the object in the image; d) determining a 2D position of the object in the image; e) determining the plane in the 3D map; f) determining, in the 3D map, at least one line of sight vector from the 3D position of the optical sensor to the object based on the projection of the 2D position of the object in the 3D map, g) determining the 3D position of the object based on the intersection of the at least one line of sight vector with the plane.
    Type: Application
    Filed: December 17, 2021
    Publication date: September 19, 2024
    Inventors: Tony NITSCHKE, Evgeni MELAN, Patrick Finn Albrecht BETHKE
  • Patent number: 12049496
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: July 30, 2024
    Assignee: Sanofi
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
  • Publication number: 20240247239
    Abstract: This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.
    Type: Application
    Filed: November 16, 2023
    Publication date: July 25, 2024
    Applicant: Moderna TX, Inc.
    Inventors: Zhijian Zhuo, Andrea Lea Frassetto, Paolo G.V. Martini, Vladimir Presnyak, Patrick Finn
  • Patent number: 11939601
    Abstract: This disclosure relates to mRNA therapy for the treatment of hyperphenylalaninemias such as phenylketonuria (PKU). mRNAs for use in the invention, when administered in vivo, encode human phenylalanine hydroxylase (PAH), functional fragments thereof (e.g., those comprising the catalytic domain or the catalytic domain and the tetramerization domains), and fusion proteins comprising PAH. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PAH expression and/or activity in subjects. mRNA therapies of the invention further decrease abnormal accumulation of phenylalanine associated with deficient PAH activity in subjects.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: March 26, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Raj Rajendran, Patrick Finn, Paolo G. V. Martini, Ding An, Athanasios Dousis, Kanchana Ravichandran
  • Publication number: 20240036569
    Abstract: System for controlling a remote controllable object, RCO, comprising a database configured to maintain remote control information regarding at least one RCO, wherein the remote control information comprises at least one remote control command of the RCO; a remote control signal sending unit configured to send at least one remote control signal comprised in the remote control command to at least one RCO via a remote control interface; a first controller operationally connected to the database, wherein the first controller is configured to retrieve the remote control information for an RCO from the database; and is configured to send remote control information via a first communication interface to a second controller; wherein the second controller is operationally connected to the remote control sending unit; and is configured to receive the remote control information from the first controller via the first communication interface; and is configured to send at least one remote control signal based on the remot
    Type: Application
    Filed: December 17, 2021
    Publication date: February 1, 2024
    Inventors: Tony NITSCHKE, Evgeni MELAN, Patrick Finn Albrecht BETHKE
  • Patent number: 11859215
    Abstract: This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: January 2, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Zhijian Zhuo, Andrea Lea Frassetto, Paolo G. V. Martini, Vladimir Presnyak, Patrick Finn
  • Publication number: 20230256062
    Abstract: The present application provides methods of treating late-onset Pompe disease (LOPD) using a pharmaceutical composition comprising an oligosaccharide-acid ?-glucosidase (GAA) conjugate, such as avalglucosidase alfa.
    Type: Application
    Filed: June 11, 2021
    Publication date: August 17, 2023
    Inventors: Patrick FINN, Alaa HAMED, Kristina AN HAACK, Catherine WILSON
  • Publication number: 20230235298
    Abstract: Variant phenylalanine hydroxylase polypeptides having substitutions at selected amino acid residues are disclosed. Also disclosed are methods of using variant phenylalanine hydroxylase polypeptides, or polynucleotides encoding variant phenylalanine hydroxylase polypeptides, to treat disorders such as phenylketonuria.
    Type: Application
    Filed: June 1, 2021
    Publication date: July 27, 2023
    Inventors: Lisa M. Rice, Patrick Finn, Athanasios Dousis
  • Publication number: 20220242899
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Application
    Filed: February 14, 2022
    Publication date: August 4, 2022
    Inventors: Luis Z. AVILA, Clark Q. PAN, Patrick FINN, John HARRAHY, Qun ZHOU, Yunxiang ZHU, Paul A. KONOWICZ, Duncan E. PATERSON, Andreas PEER, Joseph P. KUTZKO, Michael R. REARDON, James E. STEFANO, Xiaoyang ZHENG, Robert J. MILLER, Lauren YOUNG
  • Publication number: 20220195026
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Application
    Filed: December 23, 2021
    Publication date: June 23, 2022
    Applicant: SANOFI
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
  • Patent number: 11279725
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: March 22, 2022
    Assignee: Genzyme Corporation
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Patent number: 11242384
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: February 8, 2022
    Assignee: SANOFI
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
  • Publication number: 20220000856
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Application
    Filed: June 22, 2021
    Publication date: January 6, 2022
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Robert Johannes Lutjens, Terry Patrick Finn
  • Publication number: 20210244803
    Abstract: The present application provides methods of treating Pompe disease such as infantile-onset Pompe disease (IOPD) using a pharmaceutical composition comprising an oligosaccharide-acid ?-glucosidase (GAA) conjugate, such as avalglucosidase alfa. Also provided are formulations of the oligosaccharide-GAA conjugates.
    Type: Application
    Filed: February 8, 2021
    Publication date: August 12, 2021
    Inventors: Kristina AN HAACK, Patrick FINN
  • Patent number: 11071729
    Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: July 27, 2021
    Assignees: Addex Pharmaceuticals S.A., Janssen Pharmaceuticals, Inc.
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Terry Patrick Finn